Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million.
Osaka, Japan-based Takeda exercised its option to acquire Maverick and obtain its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages.
Get the full story at our sister site, Drug Delivery Business News.